Novy Hradec Kralove

• A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into … Not authorised
  2022-501644-15-00 4 Mild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disea
• A Study Providing Continued Access to Treatment in Patients with a Neurological Disease Previously Enrolled in a Genentech and/or F. Hoffman … Not authorised
  2023-507633-21-00 5 Neurological Disease
• A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral … Pending
  2024-511567-28-01 4 Cancer
• Phase 3 Study of T-DXd and Rilvegostomig versus Standard of Care in Advanced HER2-expressing Biliary Tract Cancer Recruiting
  2023-508057-19-00 5 2025-09-23 Advanced HER2-expressing Biliary Tract Cancer
• A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10 … Recruiting
  2024-512659-19-00 10 2025-03-31 Advanced Melanoma
• IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting
  2024-514517-35-00 5 2025-02-27 Acute myeloid leukemia
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting
  2023-504358-36-00 5 2024-10-17 multiple sclerosis
• A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI … Recruiting
  2024-511404-17-00 5 2024-10-07 Unresectable or metastatic NRAS mutant cutaneous melanoma
• Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting
  2022-501105-12-00 5 2024-07-15 Urothelial Carcinoma
• Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's Dis … Recruiting
  2022-502050-14-00 5 2024-06-04 Crohn's disease
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting
  2022-502548-12-00 5 2023-09-28 marginal zone lymphoma
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting
  2022-501007-28-00 5 2023-04-18 Breast Neoplasms
• A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS … Recruiting
  2022-500479-29-00 10 2023-03-28 International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with NMDAR or LGI1 mediated autoimm … Recruiting
  2023-504226-18-00 5 2022-11-30 NMDAR or LGI1 mediated autoimmune Encephalitis
• The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR … Recruiting
  2024-512119-34-00 4 2022-06-20 MSI-H/dMMR metastatic colorectal cancer
• Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with P … Recruiting
  2024-514617-35-00 4 2021-12-20 Progressive forms of Multiple Sclerosis
• An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l … Recruiting
  2024-511267-28-00 5 2021-02-17 B-cell malignancies
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM) Recruiting
  2023-505788-35-00 4 2025-06-11 Immune thrombocytopenia
• A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting
  2024-516009-22-00 5 2025-04-30 myelodysplastic neoplasms/syndromes (MDS)

Showing 1–24 of 214 trials